LA JOLLA—Mitochondria, tiny structures present in most cells, are known for their energy-generating machinery. Now, Salk researchers have discovered a new function of mitochondria: they set off molecular alarms when cells are exposed to stress or chemicals that can damage DNA, such as chemotherapy. The results, published online in Nature Metabolism on December 9, 2019, could lead to new cancer treatments that prevent tumors from becoming resistant to chemotherapy.
LA JOLLA—In mouse models of Alzheimer’s disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells. Now, Salk researchers have shown how these compounds can also slow aging in healthy older mice, blocking the damage to brain cells that normally occurs during aging and restoring the levels of specific molecules to those seen in younger brains.
LA JOLLA—While scientists know of about 25,000 genes that code for biologically important proteins, additional, smaller genes hiding in our DNA may be just as important. But these tiny lines of genetic code have proven tough to track down.
LA JOLLA—Bright light at night interrupts the body’s normal day-night cycles, called circadian rhythms, and can trigger insomnia. In fact, circadian rhythms play a major role in health. Disrupted day-night cycles have even been linked to increased incidence of diseases like cancer, heart disease, obesity, depressive disorders and type 2 diabetes in people who work night shifts. Therefore, understanding how human eyes sense light could lead to “smart” lights that can prevent depression, foster sleep at night, and maintain healthy circadian rhythms.
LA JOLLA—Metabolic syndrome affects nearly 30 percent of the U.S. population, and increases the risk for type 2 diabetes, heart disease and stroke. But lifestyle interventions such as adopting a healthy diet and increasing physical exercise are difficult to maintain and, even when combined with medication, are often insufficient to fully manage the disease.
LA JOLLA—Metformin is the most commonly prescribed type 2 diabetes drug, yet scientists still do not fully know how it works to control blood sugar levels. In a collaborative effort, researchers from the Salk Institute, The Scripps Research Institute and Weill Cornell Medical College have used a novel technology to investigate why it functions so well. The findings, which identified a surprising number of biochemical “switches” for various cellular processes, could also explain why metformin has been shown to extend health span and life span in recent studies. The work was published in Cell Reports on December 3, 2019.
LA JOLLA—Salk Professors Joanne Chory, Joseph Ecker, Ronald Evans, Rusty Gage, Juan Carlos Izpisua Belmonte, Terrence Sejnowski, Reuben Shaw and Kay Tye have been named to the Highly Cited Researchers list by Clarivate Analytics. The list selects researchers for demonstrating “significant and broad influence” reflected by the production of multiple highly cited papers that rank in the top 1 percent by citations for field and year.
LA JOLLA—Although alcohol use is ubiquitous in modern society, only a portion of individuals develop alcohol use disorders or addiction. Yet, scientists have not understood why some individuals are prone to develop drinking problems, while others are not. Now, Salk Institute researchers have discovered a brain circuit that controls alcohol drinking behavior in mice, and can be used as a biomarker for predicting the development of compulsive drinking later on. The findings were published in Science on November 21, 2019, and could potentially have implications for understanding human binge drinking and addiction in the future.
LA JOLLA—Salk Professor Emeritus Jean Rivier, who pioneered studies on the characterization of the hypothalamic peptides that control the stress response, and developed drugs that target this response, passed away peacefully in San Diego, California, on November 13, 2019.
LA JOLLA—For the ninth consecutive time, the Salk Institute has earned the highest ranking—4 out of 4 stars—from Charity Navigator, America’s largest independent charity and nonprofit evaluator. Only three percent of the roughly 10,000 nonprofits evaluated have achieved this recognition for nine consecutive times. The coveted ranking indicates the Salk Institute outperforms most other charities in America in regard to executing best fiscal practices and carrying out its mission in a financially efficient way.
LA JOLLA—The Salk Institute announced today that it received more than $89 million from 1,204 individual donors and private grant makers in fiscal year 2019 (ending in June) to support the Institute’s world-renowned science. The amount is the most raised from private donors in the past decade and accounts for 49 percent of Salk’s FY19 revenue.
LA JOLLA—Little is known about the molecular and cellular events that occur during early embryonic development in primate species. Now, an internationally renowned team of scientists in China and the United States has created a method to allow primate embryos to grow in the laboratory longer than ever before, enabling the researchers to obtain molecular details of key developmental processes for the first time. This research, while done in nonhuman primate cells, can have direct implications for early human development.
LA JOLLA—A new podcast series called Where Cures Begin launches this week and features one-on-one conversations with Salk researchers working at the forefront of their respective scientific fields, from cancer and neuroscience to plant biology, circadian science and more. The eight episodes of season 1, which will be released weekly beginning October 30, 2019, include interviews with the following Salk scientists:
LA JOLLA—As the tools to study biology improve, researchers are beginning to uncover details into microproteins, small components that appear to be key to some cellular processes, including those involved with cancer. Proteins are made up of chains of linked amino acids and the average human protein contains around 300 amino acids. Meanwhile, microproteins have fewer than 100 amino acids.
LA JOLLA—Salk Institute scientists Nicola Allen, Eiman Azim, Margarita Behrens, and Joseph Ecker have been named recipients in the 2019 round of grants from the National Institutes of Health (NIH) to better understand the brain.
LA JOLLA, CA—A team of Salk scientists led by Professor Martyn Goulding has been awarded $14.3 million over five years by the National Institutes of Health (NIH) to create a high-resolution atlas of how the mouse brain generates and controls skilled forelimb movements, such as reaching and grasping. Knowledge generated by the grant will provide a better understanding of not only how the brain controls movement, but also how it is affected by neurological diseases and spinal cord injuries that compromise arm, wrist and hand function.
LA JOLLA—Although graduating from school, a first job and marriage can be important events in life, some of the most significant events happen far earlier: in the first few days after a sperm fertilizes an egg and the cell begins to divide.
LA JOLLA—In recent decades, scientists have learned a great deal about how different neurons connect and send signals to each other. But it’s been difficult to trace the activity of individual nerve fibers known as axons, some of which can extend from the tip of the toe to the head. Understanding these connections is important for figuring out how the brain receives and responds to signals from other parts of the body.
LA JOLLA, CA—Salk scientist Tony Hunter has received a National Cancer Institute (NCI) Outstanding Investigator Award (OIA), which supports accomplished leaders in cancer research. Hunter, who is an American Cancer Society Professor, will receive more than $7,500,000 over the next seven years to further his work. According to the NCI, the award supports investigators who are providing significant contributions toward understanding cancer and developing applications that may lead to a breakthrough in cancer research.
LA JOLLA—Breast cancer is one of the most prevalent cancers, and some forms rank among the most difficult to treat. Its various types and involvement of many different cells makes targeting such tumors difficult. Now, Salk Institute researchers have used a state-of-the-art technology to profile each cell during normal breast development in order to understand what goes wrong in cancer.